Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Vantage Pharma, Biotech & Medtech 2019 in Review
2019 was a standout year for biopharma, anchored by strong fourth quarter markets and dealmaking. Following a difficult end to 2018, the biopharma industry recovered impressively to achieve an excellent 2019. A fourth-quarter surge on the stock markets meant that many companies ended the year on a high note, as investors flocked to drug developers…
Report library
Vantage 2019 Preview
2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…
First-line lung cancer: can Keytruda be stopped?
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC. 2018 started with the promise of a first-line lung…
EvaluateMedTech World Preview 2018, Outlook to 2024
Report Highlights Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players Neurology set to be the…
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of…
EvaluatePharma World Preview 2018, Outlook to 2024
Report Highlights Worldwide prescription drug sales accelerate to $1.2 trillion by 2024, as unmet need drives annual compound growth to over 6% R&D spend is…
